Literature DB >> 2070793

Autoprocessing of the HIV-1 protease using purified wild-type and mutated fusion proteins expressed at high levels in Escherichia coli.

J M Louis1, R A McDonald, N T Nashed, E M Wondrak, D M Jerina, S Oroszlan, P T Mora.   

Abstract

Various constructs of the human immunodeficiency virus, type 1 (HIV-1) protease containing flanking Pol region sequences were expressed as fusion proteins with the maltose-binding protein of the malE gene of Escherichia coli. The full-length fusion proteins did not exhibit self-processing in E. coli, thereby allowing rapid purification by affinity chromatography on cross-linked amylose columns. Denaturation of the fusion protein in 5 M urea, followed by renaturation, resulted in efficient site-specific autoprocessing to release the 11-kDa protease. Rapid purification involving two column steps gave an HIV-1 protease preparations of greater than 95% purity (specific activity approximately 8500 pmol.min-1.micrograms protease-1) with an overall yield of about 1 mg/l culture. Incubation of an inactive mutant protease fusion protein with the purified wild-type protease resulted in specific trans cleavage and release of the mutant protease. Analysis of products of the HIV-1 fusion proteins containing mutations at either the N- or the C-terminal protease cleavage sites indicated that blocking one of the cleavage sites influences the cleavage at the non-mutated site. Such mutated full-length and truncated protease fusion proteins possess very low levels of proteolytic activity (approximately 5 pmol.min-1.micrograms protein-1).

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2070793     DOI: 10.1111/j.1432-1033.1991.tb16132.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  20 in total

1.  Escherichia coli maltose-binding protein is uncommonly effective at promoting the solubility of polypeptides to which it is fused.

Authors:  R B Kapust; D S Waugh
Journal:  Protein Sci       Date:  1999-08       Impact factor: 6.725

2.  Single amino acid substitutions on the surface of Escherichia coli maltose-binding protein can have a profound impact on the solubility of fusion proteins.

Authors:  J D Fox; R B Kapust; D S Waugh
Journal:  Protein Sci       Date:  2001-03       Impact factor: 6.725

3.  Human immunodeficiency virus type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro.

Authors:  M Kotler; M Simm; Y S Zhao; P Sova; W Chao; S F Ohnona; R Roller; C Krachmarov; M J Potash; D J Volsky
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

4.  Processing of avian retroviral gag polyprotein precursors is blocked by a mutation at the NC-PR cleavage site.

Authors:  H Burstein; D Bizub; M Kotler; G Schatz; V M Vogt; A M Skalka
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

5.  HIV-1 protease dimer interface mutations that compensate for viral reverse transcriptase instability in infectious virions.

Authors:  Isabel Olivares; Alok Mulky; Peter I Boross; József Tözsér; John C Kappes; Cecilio López-Galíndez; Luis Menéndez-Arias
Journal:  J Mol Biol       Date:  2007-07-03       Impact factor: 5.469

6.  Optimized Procedure for Recovering HIV-1 Protease (C-SA) from Inclusion Bodies.

Authors:  Sibusiso B Maseko; Deidre Govender; Thavendran Govender; Tricia Naicker; Johnson Lin; Glenn E M Maguire; Hendrik G Kruger
Journal:  Protein J       Date:  2019-02       Impact factor: 2.371

7.  HIV-I protease. Cloning, expression, and purification.

Authors:  N I Dergousova; A M Volynskaya; L D Rumsh
Journal:  Appl Biochem Biotechnol       Date:  1996 Oct-Nov       Impact factor: 2.926

8.  Importance of the N terminus of rous sarcoma virus protease for structure and enzymatic function.

Authors:  G W Schatz; J Reinking; J Zippin; L K Nicholson; V M Vogt
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

9.  Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors.

Authors:  R E Rose; Y F Gong; J A Greytok; C M Bechtold; B J Terry; B S Robinson; M Alam; R J Colonno; P F Lin
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-20       Impact factor: 11.205

10.  Human immunodeficiency virus type 1 gag-protease fusion proteins are enzymatically active.

Authors:  M Kotler; G Arad; S H Hughes
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.